Venlafaxine 25 mg Tablets Under Non-Fasting Conditions

Randomized, 2-Way Crossover, Bioequivalence Study of Venlafaxine 25 mg Tablets and Effexor® 25 mg Tablets Administered as 1 x 25 mg Tablet in Healthy Subjects Under Fed Conditions

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00834249

Enrollment

Registered

2009-02-03

Start date

2002-12-31

Completion date

2002-12-31

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Bioequivalence, Healthy Subjects

Brief summary

The objective of this study is to compare the rate and extent of absorption of venlafaxine 25 mg tablets (test) versus Effexor® (reference) administered as 1 x 25 mg tablet under fed conditions.

Detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria Statistical Methods: FDA bioequivalence statistical methods

Interventions

DRUGVenlafaxine 25 mg Tablets

1 x 25 mg, single-dose fasting

DRUGEffexor® 25 mg Tablets

1 x 25 mg, single-dose fasting

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Subjects will be females and/or males, non-smokers, 18 years of age and older. Female subjects will be post-menopausal or surgically sterilized. * Post-menopausal status is defined as absence of menses for the past 12 months or hysterectomy with bilateral oophorectomy at least 6 months ago. * Sterile status is defined as hysterectomy, bilateral oophorectomy or tubal ligation at least 6 months ago.

Exclusion criteria

* Clinically significant illnesses within 4 weeks of the administration of study medication. * Clinically significant surgery within 4 weeks of the administration of study medication. * Any clinically significant abnormality found during medical screening. * Any reason which, in the opinion of the medical sub-investigator, would prevent the subject from participating in the study. * Abnormal laboratory tests judged clinically significant. * Positive urine drug screen at screening. * Positive testing for hepatitis B, hepatitis C, or HIV at screening. * ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, or diastolic blood pressure lower than 50 or over 90 mmHg; or heart rate less than 50 or over 100 bpm) at screening. * Subjects with BMI ≥ 30.0. * History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than fourteen units of alcohol per week (1 Unit - 150 mL of wine or 360 mL of beer or 45 mL of alcohol 40%). * History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana) within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine (PCP) and crack) within 1 year of the screening visit. * History of allergic reactions to venlafaxine. * History of allergic reactions to heparin. * Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin; examples of inhibitors: antidepressants, cimetidine, diltiazem, erythromycin, ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine) within 30 days prior to administration of the study medication. * Use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication. * History or presence of any clinically significant gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney disease or other conditions known to interfere with the absorption, distribution, metabolism or excretion of the drug. * Any history or presence of clinically significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease. * Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products (including natural food supplements, vitamins, garlic as a supplement) within 7 days prior to administration of study medication, except for topical products without systemic absorption. * Positive alcohol breath test at screening. * Subjects who have used tobacco in any form within the 90 days preceding study drug administration. * Intolerance to venipuncture. * Subjects with a clinically significant history of tuberculosis, epilepsy, asthma, diabetes, psychosis, or glaucoma will not be eligible for this study. * Subjects who are unable to understand or unwilling to sign the Informed Consent Form. * Any food allergy, intolerance, restriction or special diet that, in the opinion of the medical sub-investigator, contraindicates the subject's participation in this study. * Subjects who have had a depot injection or an implant of any drug 3 months prior to administration of study medication. * Donation of plasma (500 mL) within 7 Days. Donation or loss of whole blood prior to administration of the study medication as follows: less than 300 mL of whole blood within 30 days or; 300 mL to 500 mL of whole blood within 45 days or; more than 500 mL of whole blood within 56 days. * Subjects who have consumed food or beverages containing grapefruit (e.g. fresh, canned, or frozen) within 7 days prior to administration of the study medication. * Subjects with known presence of volume-depletion. * Subjects predisposed to bleeding of the skin and mucous membrane. * Subjects with history or known presence of impaired platelet aggregation. * Subjects with history of seizures. * Breast-feeding subjects. * Positive urine pregnancy test at screening (performed on all females).

Design outcomes

Primary

Measure	Time frame	Description
Cmax - Maximum Observed Concentration - Venlafaxine in Plasma	Blood samples collected over 24 hour period	Bioequivalence based on Cmax
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Venlafaxine in Plasma	Blood samples collected over 24 hour period	Bioequivalence based on AUC0-inf
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Venlafaxine in Plasma	Blood samples collected over 24 hour period	Bioequivalence based on AUC0-t

Secondary

Measure	Time frame	Description
Cmax - O-Desmethylvenlafaxine in Plasma	Blood samples collected over 24 hour period	Informational Purposes Only
AUC0-inf - O-desmethylvenlafazine in Plasma	Blood samples collected over 24 hour period	Informational Purposes Only
AUC0-t - O-desmethylvenlafaxine in Plasma	Blood samples collected over 24 hour period	Informational Purposes Only

Countries

Canada

Participant flow

Participants by arm

Arm	Count
Venlafaxine (Test) First Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period	9
Effexor® (Reference) First Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period	9
Total	18

Withdrawals & dropouts

Period	Reason	FG000	FG001
Second Intervention	Adverse Event	1	0
Washout: 7 Days	Withdrawal by Subject	1	1

Baseline characteristics

Characteristic	Venlafaxine (Test) First	Effexor® (Reference) First	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	0 Participants	0 Participants	0 Participants
Age, Categorical Between 18 and 65 years	9 Participants	9 Participants	18 Participants
Race/Ethnicity, Customized Black	1 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized Caucasian	8 Participants	9 Participants	17 Participants
Region of Enrollment Canada	9 participants	9 participants	18 participants
Sex: Female, Male Female	3 Participants	4 Participants	7 Participants
Sex: Female, Male Male	6 Participants	5 Participants	11 Participants